An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway

In clinical practice, some breast cancer (BC) patients carry a rare ERBB2 in-frame insertion (p. Pro780_Tyr781insGlySerPro) and are resistant to anti-ERBB2 therapy. To explore the potential procarcinogenic role of this ERBB2 mutation, we conducted the present study using BC cells overexpressing wild...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zi-Yan, Yang, Liu, Xu, Chun-Wei, Wang, Xiao-Jia, Lei, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994922/
https://www.ncbi.nlm.nih.gov/pubmed/31980423
http://dx.doi.org/10.1242/bio.047662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994922/
https://www.ncbi.nlm.nih.gov/pubmed/31980423
http://dx.doi.org/10.1242/bio.047662

Ejemplares similares